Novo Nordisk ends collaboration with Hims & Hers over weight loss drug sale
COPENHAGEN, June 23 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it would halt its collaboration with Hims & Hers Health (HIMS.N), opens new tab over the sale of weight loss drugs.
The two companies had announced a collaboration in April for Hims & Hers to sell Novo's blockbuster Wegovy weight loss drug through a bundled offering on the telehealth company's platform.
Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health via the NovoCare Pharmacy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
25 minutes ago
- Reuters
ECB's Nagel says bond-buying is only for exceptional cases
FRANKFURT, June 23 (Reuters) - The European Central Bank should only engage in massive bond buying in "absolutely exceptional cases" after this form of monetary stimulus caused it to report major losses, ECB policymaker Joachim Nagel said on Monday. The Bundesbank's president was joining a growing number of policymakers in signalling the ECB wanted to turn the page on the aggressive-money printing policy that marked the last decade, when inflation in the euro zone was too low. "In light of the latest experience, we should deploy the instrument of large-scale asset purchases at the lower bound for interest rates in absolutely exceptionally cases in the future," Nagel said in a speech. Having vanquished high inflation, the ECB is reviewing its long-term strategy, including the role of massive bond purchases, or quantitative easing (QE). An announcement is expected in coming weeks. The ECB bought 5 trillion euros ($5.77 trillion) worth of debt in 2014-21, a wave of money printing that has been criticised for creating bubbles in property and financial markets. When inflation and interest rates eventually rose, the ECB and its shareholding central banks, particularly the Bundesbank, ended up paying high interest on the reserves they had created while collecting little income from the bonds. ECB vice-president Luis de Guindos told Reuters earlier this month the central bank had "learned much more" about the side effects of its stimulus policies. Croatia's central bank governor Boris Vujcic said "the bar for QE would be higher" in the future. ECB President Christine Lagarde said in the European Parliament on Monday the central bank "certainly prefer(red) to use interest rates" over QE as its policy tool. ($1 = 0.8673 euros)
The Independent
32 minutes ago
- The Independent
Wegovy manufacturer ends deal with Hims & Hers to distribute weight loss drug
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the popular weight-loss drug, Wegovy. The Danish pharmaceutical giant and Hims & Hers had initially partnered in April, with plans for the telehealth company to offer Wegovy as part of a bundled package on its platform. Despite the halt, Hims & Hers stated earlier this month that it intends to continue selling "personalised" doses of Wegovy, priced from approximately $165 a month. This approach, according to Hims, is permissible under clinical guidelines, citing reasons such as reduced side effects. Hims also provides liraglutide, a generic version of an older Novo Nordisk diabetes medication known for its weight-loss effects, alongside branded Wegovy and Eli Lilly's competing drug, Zepbound. Wall Street analysts have questioned whether Hims' offerings actually qualify as "personalized" and say it is unclear if Novo, which has said mass production of copies is breaking the law, will allow it. Hims & Hers was not immediately available for a comment outside of the company's regular work hours. A U.S. federal judge on Friday rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's decision to remove the drugs' active ingredient, semaglutide, from the shortage list. "Efforts will continue to make authentic, FDA-approved Wegovy directly available through NovoCare Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients," Novo said. Novo's share price fell following the announcement, extending an earlier decline to trade down 6.5% by 1315 GMT. Shares of Hims and Hers fell 22% to $50.02 in U.S. premarket hours.
The Sun
33 minutes ago
- The Sun
Fat loss pill that can help you ‘lose weight AND tone up' set to rival jabs
A PILL to make you buff is a step nearer to reality as inventors move onto the next phase of human trials. Scientists say the drug, currently known as ATR-258, can burn off fat but save muscle. 1 It would overcome an issue with fat jabs such as Mounjaro which shrink muscle as well as flab. This can leave people weak and make them look more skinny or saggy. Preserving muscle while fat burns off could help slimmers stay toned, as well as boosting their health. Professor Tore Bengtsson, founder of manufacturer Atrogi, said: 'This pill can actively reshape body composition, reducing fat while preserving muscle mass, all without requiring dietary restriction. 'That's unprecedented.' Large human trial to test effects The drug was invented to treat obesity and type 2 diabetes. Results of the first phase trial, on 48 patients, were published in the journal Cell and showed it was safe for humans to take. Prof Bengtsson, also of Stockholm University, now plans to trial it on a bigger group of overweight people to see if it works as well as it did in animal studies. It functions by triggering the metabolism in the muscles, activating them to burn more fat. This is different to injections like Ozempic, which use hormones in the brain to banish hunger. Two thirds of adults in the UK are overweight or obese and the issue has rocketed since the 1990s. Prof Bengtsson said: 'Our results point to a future where we can improve metabolic health without losing muscle mass. 'Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.' NHS MOUNJARO ROLLOUT BEGINS FROM Monday, June 23, so-called 'fat jabs' will be made available to many more Brits on the NHS. GPs will begin prescribing the weight-loss jab Mounjaro in the first anti- obesity rollout of its kind. Previously it was only available for type 2 diabetes, while Wegovy was distributed by specialist slimming clinics. Top of the list for prescriptions will be those with a body mass index (BMI) of 40 or higher and four weight-related health conditions. A BMI of 40 is roughly equal to weighing 16st (102kg) for an average height 5'3' woman, or 19st 6lbs (123kg) for an average 5'9' man. Weight-related conditions include high cholesterol, high blood pressure, prediabetes, type 2 diabetes, obstructive sleep apnoea and heart disease. Patients will likely be expected to have tried diet and exercise first before being offered a jab. Many are likely to miss out, as some 13.5million adults in England are obese but only 3.4million are estimated to be eligible in the rollout.
